My Profile

Search abstracts

Lewis Sheiner


2017
Budapest, Hungary



2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
KÝbenhavn, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland



Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

Reference:
PAGE 21 (2012) Abstr 2383 [www.page-meeting.org/?abstract=2383]


PDF poster/presentation:
Click to open Click to open

Poster: Other Drug/Disease Modelling


IV-04 Nicolas Frey Short- and Long-Term Effects of Tocilizumab on Neutrophil Counts in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis

Nicholas Frey (1), Olivier Harari (2) and Leonid Gibiansky (3)

(1) F. Hoffmann-La Roche Ltd, Basel, Switzerland; (2) Roche Products Ltd, Welwyn, United Kingdom; (3) QuantPharm LLC, North Potomac, MD, USA

Objectives: Tocilizumab (TCZ) is a recombinant humanized IL-6 receptor monoclonal antibody that inhibits binding of IL-6 to its receptors. The aim of the analysis was to describe the time course of peripheral neutrophil counts (NTC) after TCZ administration in a pediatric population.

Methods: Serum TCZ concentrations and NTC were available from 75 patients with active systemic juvenile idiopathic arthritis (sJIA) who received 12 mg/kg (for patients < 30 kg) or 8 mg/kg (for patients ≥ 30 kg) infusions of TCZ every 2 weeks (total of 6 doses). Neutrophil counts were assessed at screening, baseline (week 0), and at 1, 2, 3, 6, 8, 10 and 12 weeks. A previously developed two-compartment model with parallel linear and Michaelis-Menten elimination described TCZ concentrations [1, 2]. Different PKPD models with direct and indirect response were tested to characterize the TCZ-NTC relationship.

Results: The TCZ-NTC relationship was described by a model that included an immediate TCZ effect on NTC decline (possibly, neutrophil margination [3]) and a longer term TCZ effect on NTC decline (toward normal levels) due to the improvement of patients' condition (e.g. decrease of inflammation). The immediate effect was described by a direct sigmoid Emax model (Emax = 0.724 (%RSE 14.8%) and EC50 = 6.38 µg/mL (%RSE 15.8%)). The PKPD parameters were very similar to the respective values obtained earlier for adult patients [2] (Emax = 0.788 and EC50 = 7.49 mcg/mL). The maximum rate of decline of the long term effect was 0.166 day-1 and the TCZ concentration corresponding to half of this rate was 151 µg/mL. The corresponding NTC decline for a typical patient was estimated to go from 8.12×109/L to 5.72×109/L. Diagnostic plots and predictive check simulations indicated a good agreement of model predictions with the observed data.

Conclusions: The NTC time course following TCZ administration in pediatric patients with sJIA was characterized by a combination of an immediate response corresponding to the direct blockade of the IL-6 signaling pathway and a slow decline possibly related to the improvement of the patients' condition (e.g. decrease of inflammation)

References:
[1] Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010 Jul;50(7):754-66. Epub 2010 Jan 23.
[2] Roche Internal Documents.
[3] Gibiansky L, Frey N. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach, J Pharmacokinet Pharmacodyn. 2012 Feb; 39(1):5-16. Epub 2011 Nov 19.